Guo‐Huan Yang

3.1k total citations · 1 hit paper
38 papers, 2.1k citations indexed

About

Guo‐Huan Yang is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Guo‐Huan Yang has authored 38 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Molecular Biology and 12 papers in Cancer Research. Recurrent topics in Guo‐Huan Yang's work include Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Cancer Mechanisms and Therapy (7 papers). Guo‐Huan Yang is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Cancer Mechanisms and Therapy (7 papers). Guo‐Huan Yang collaborates with scholars based in China, Ethiopia and United States. Guo‐Huan Yang's co-authors include Jia Fan, Jian Zhou, Zhi Dai, Xiaowu Huang, Shao‐Lai Zhou, Xin‐Rong Yang, Zhao–You Tang, Shuang–Jian Qiu, Xiaoying Wang and Hui‐Chuan Sun and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Clinical Cancer Research.

In The Last Decade

Guo‐Huan Yang

35 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma

2011 521 citations Jian Zhou, Lei Yu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guo‐Huan Yang China	17	952	773	732	504	334	38	2.1k
Guo‐Ming Shi China	30	1.8k 1.9×	1.2k 1.6×	740 1.0×	483 1.0×	332 1.0×	71	3.0k
Aurélie Hérault France	12	808 0.8×	394 0.5×	337 0.5×	433 0.9×	339 1.0×	15	1.7k
Atsushi Takai Japan	22	560 0.6×	418 0.5×	435 0.6×	395 0.8×	193 0.6×	69	1.5k
Laura Galluzzo Argentina	13	876 0.9×	600 0.8×	425 0.6×	383 0.8×	175 0.5×	40	1.6k
Henning Wege Germany	20	660 0.7×	345 0.4×	526 0.7×	430 0.9×	219 0.7×	64	1.8k
Orlando Musso France	23	812 0.9×	478 0.6×	427 0.6×	403 0.8×	138 0.4×	40	1.6k
Luca Emanuele Pollina Italy	22	750 0.8×	566 0.7×	1.1k 1.5×	495 1.0×	86 0.3×	63	2.1k
Carla Cicchini Italy	26	1.6k 1.6×	926 1.2×	418 0.6×	359 0.7×	138 0.4×	61	2.4k
Marc Ringelhan Germany	14	588 0.6×	298 0.4×	452 0.6×	536 1.1×	629 1.9×	25	1.7k
Raleigh D. Kladney United States	23	996 1.0×	434 0.6×	505 0.7×	219 0.4×	281 0.8×	33	1.8k

Countries citing papers authored by Guo‐Huan Yang

Since Specialization

Citations

This map shows the geographic impact of Guo‐Huan Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guo‐Huan Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guo‐Huan Yang more than expected).

Fields of papers citing papers by Guo‐Huan Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guo‐Huan Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guo‐Huan Yang. The network helps show where Guo‐Huan Yang may publish in the future.

Co-authorship network of co-authors of Guo‐Huan Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Guo‐Huan Yang. A scholar is included among the top collaborators of Guo‐Huan Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guo‐Huan Yang. Guo‐Huan Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

He, Yifeng, Xiaowu Huang, Xiaoyong Huang, et al.. (2025). Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors after transplant: A prospective pilot trial. Liver Transplantation. 32(2). 135–143.

Zheng, Yi-Min, Chao Gao, Wenxin Xu, et al.. (2025). The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC. Hepatology. 83(4). 771–788.

Zhang, Hao, Chi Zhang, Li Lin, et al.. (2025). Small pulmonary nodule localization techniques in the era of lung cancer screening: a narrative review. International Journal of Surgery. 111(3). 2624–2632. 3 indexed citations

Huang, Xiaoyong, Guo‐Ming Shi, Hui‐Chuan Sun, et al.. (2025). Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study. BMC Medicine. 23(1). 573–573.

Han, Yanchao, et al.. (2025). External Sucrose Delays Pakchoi Senescence Through Regulating Energy Metabolism. Journal of Food Processing and Preservation. 2025(1). 1 indexed citations

Ji, Feng, Xiwen Liao, Yong Wu, et al.. (2024). The prognostic role of ACSL4 in postoperative adjuvant TACE-treated HCC: implications for therapeutic response and mechanistic insights. Journal of Experimental & Clinical Cancer Research. 43(1). 306–306. 4 indexed citations

Yang, Guo‐Huan, Isabelle C. Kos‐Braun, Marta Gomes da Rocha, et al.. (2024). 2′-O-ribose methylation levels of ribosomal RNA distinguish different types of growth arrest in human dermal fibroblasts. Journal of Cell Science. 137(3). 5 indexed citations

Guo, Xiaojun, Xiaoyong Huang, Xuan Yang, et al.. (2023). Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis. Cell Death and Disease. 14(2). 79–79. 14 indexed citations

Huang, Ao, De‐Zhen Guo, Ying Sun, et al.. (2023). Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer. Hepatology International. 18(1). 254–264. 7 indexed citations

10.

Zhou, Wenshuo, Linglei Jiang, Feifei Wu, et al.. (2023). Vaccines’ New Era-RNA Vaccine. Viruses. 15(8). 1760–1760. 31 indexed citations

11.

Guo, Xiaojun, Jia‐Cheng Lu, Haiying Zeng, et al.. (2021). CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. Frontiers in Immunology. 12. 705378–705378. 26 indexed citations

12.

Wang, Zheng, Zhenggang Ren, Yi Chen, et al.. (2018). Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. Clinical Cancer Research. 24(9). 2074–2081. 204 indexed citations

13.

Huang, Xianqing, et al.. (2017). GacS/GacA activates pyoluteorin biosynthesis through Gac/Rsm‐RsmE cascade and RsmA/RsmE‐driven feedback loop in Pseudomonas protegens H78. Molecular Microbiology. 105(6). 968–985. 18 indexed citations

14.

Shen, Ying‐Hao, Si Chen, Yuan‐Fei Peng, et al.. (2014). Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk. Tumor Biology. 35(5). 4007–4015. 18 indexed citations

15.

Zhou, Shao‐Lai, Zhi Dai, Zheng‐Jun Zhou, et al.. (2013). CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils. Carcinogenesis. 35(3). 597–605. 136 indexed citations

16.

Zhou, Shao‐Lai, Zhi Dai, Zheng‐Jun Zhou, et al.. (2012). Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 56(6). 2242–2254. 292 indexed citations

17.

Zhu, Kai, Zhi Dai, Qi Pan, et al.. (2011). Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition. Clinical Cancer Research. 17(23). 7294–7302. 122 indexed citations

18.

Shi, Guo‐Ming, Ai‐Wu Ke, Jian Zhou, et al.. (2010). CD151 Modulates Expression of Matrix Metalloproteinase 9 and Promotes Neoangiogenesis and Progression of Hepatocellular Carcinoma. Hepatology. 52(1). 183–196. 106 indexed citations

19.

Yang, Xin‐Rong, Yang Xu, Bin Yu, et al.. (2009). CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery. Clinical Cancer Research. 15(17). 5518–5527. 129 indexed citations

20.

Hu, Jie, Yang Xu, Zheng Wang, et al.. (2009). High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. Journal of Cancer Research and Clinical Oncology. 135(10). 1359–1367. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact